Alternative medicine clinic in Mexico
Clinica 0-19 is a medical clinic in Monterrey, Mexico that claims to treat diffuse intrinsic pontine glioma (DIPG). Although DIPG is currently regarded as one of the most devastating pediatric cancers, with a survival rate of ;1% over five years, the clinic states that their treatment, which can cost hundreds of thousands of dollars, has resulted in some patients no longer having any evidence of disease. However, there is no credible evidence to support their claims and at least some of their patients were found to have tumor growth a few months later. Oncologists and others have criticized the clinic's lead doctors, Alberto Siller and Alberto Garcia, for their lack of transparency, for not publishing their treatment protocol or survival rates, for the high costs of treatment, and for discouraging their patients from using radiation therapy.
Treatment of diffuse intrinsic pontine glioma.
Clinica 0-19 treats DIPG with intra-arterial chemotherapy and immunotherapy. While consultation and follow-up appointments take place at Clinica 0-19, treatments are carried out at nearby hospitals, especially Hospital Angeles.
For the intra-arterial chemotherapy, a catheter is inserted into the femoral artery, guided to the patient's brainstem, and used to deliver chemotherapy drugs. The clinic has stated the drugs they use are FDA approved. Their website does not provide any examples of the kinds of drugs, but drugs they have employed in the past have included unusually low doses of cisplatin, cetuximab, doxorubicin, and Avastin. None of these drugs have been shown to be effective against DIPG, and it is unclear if Avastin has been approved by the FDA for use in children. According to the parents of one patient interviewed in 2018, the doctors administer "10 to 12 different types of medicines." Treatment is provided once every three weeks in some cases and once every six weeks in other cases for a total of ten or more times.
The immunotherapy provided by the clinic uses dendritic cells, but very little has been published on the use of dendritic cells to treat DIPG. 
Siller and Garcia have not published their protocol for treatment. They characterize their approach as tailoring the treatment to each child. Surgical oncologist and outspoken opponent of alternative medicine, David Gorski has criticized this approach, stating "In other words, we make it up as we go along and can’t tell you how we do it in a sufficiently clear manner to make it possible to write a protocol to do it in a clinical trial."
The clinic has also been criticized for discouraging their patients from using radiation therapy. 
Efficacy.
No studies have been conducted on Clinica 0-19's approach to treating DIPG, and the clinic has not provided information on their patients' survival or recurrence rates.
The clinic has released scans appearing to show that patients' tumors have shrunk following treatment at the clinic. Dr. David Ziegler, an Australian pediatric oncologist, has stated the scans "do not accurately depict the tumor." Gorski has noted the apparent shrinking could be the abatement of inflammation around the tumor caused by previous treatment.
Media coverage of the clinic has highlighted cases of patients who, following treatment by Siller and Garcia, lived longer than was initially expected. Gorski has noted that children receiving care at the clinic may have been likely to live longer than average DIPG patients, regardless of treatment by Clinica 0-19, because the clinic only treats patients who can travel to the clinic, forgo treatment with steroids for several months prior to treatment, and who can afford the hundreds of thousands of dollars charged by the clinic for treatment. Gorski also notes that patients who are able to travel abroad and thrive without steroids are likely in better health than the average DIPG patient, and that families that can access large amounts of money for treatment may not be typical of DIPG patients in other ways that could impact their survival.
Criticism.
Ziegler and Gorski have criticized Siller and Garcia for not publishing their results or treatment protocol.
Australia's Cure Brain Cancer Foundation (CBCF) sought to visit Clinica 0-19 to research the treatment it provides in March 2018. CBCF has also offered to assist the clinic in reporting their findings. A spokesperson for the clinic stated the doctors would need to develop a program to receive visiting doctors before they could work with the CBCF. As of January 2019, there was no evidence that such visits have been planned. CBCF have stated "With regard to the current news reports about Clinica 0-19 in Mexico, it is not possible for us to recommend that clinic’s approach given that Doctors Siller and Garcia have not yet published any data for critical review about their treatments."
In February 2018, Siller stated the clinic had "started to do some basic numbers" with the intention of publishing their results "in the next coming months."
Media coverage of patients.
Several Clinica 0-19 patients have been the subject of media coverage:
References.
 ;templatestyles src="Reflist/styles.css" / ;